Osimertinib in patients with epidermal growth factor receptor mutation–positive non–small-cell lung cancer and leptomeningeal metastases: the BLOOM study

JCH Yang, SW Kim, DW Kim, JS Lee… - Journal of Clinical …, 2020 - ascopubs.org
PURPOSE In this phase I study (BLOOM), osimertinib, a third-generation epidermal growth
factor receptor (EGFR) tyrosine kinase inhibitor (TKI), was evaluated in patients with …
被引用次数：277 相关文章

Osimertinib in patients with epidermal growth factor receptor mutation-positive non-small-cell lung cancer and leptomeningeal metastases: The BLOOM study

JCH Yang, SW Kim, DW Kim, JS Lee… - Journal of Clinical …, 2020 - snucm.elsevierpure.com
PURPOSE In this phase I study (BLOOM), osimertinib, a third-generation epidermal growth
factor receptor (EGFR) tyrosine kinase inhibitor (TKI), was evaluated in patients with …

Osimertinib in Patients With Epidermal Growth Factor Receptor Mutation? Positive Non? Small-Cell Lung Cancer and Leptomeningeal Metastases: The BLOOM Study

JCH Yang, SW Kim, DW Kim, JS Lee… - JOURNAL OF …, 2020 - scholarworks.bwise.kr
PURPOSE In this phase I study (BLOOM), osimertinib, a third-generation epidermal growth
factor receptor (EGFR) tyrosine kinase inhibitor (TKI), was evaluated in patients with …

Osimertinib in patients with epidermal growth factor receptor mutation-positive non-small-cell lung cancer and leptomeningeal metastases: The BLOOM study

JCH Yang, SW Kim, DW Kim, JS Lee… - Journal of Clinical …, 2020 - s-space.snu.ac.kr
PURPOSE In this phase I study (BLOOM), osimertinib, a third-generation epidermal growth
factor receptor (EGFR) tyrosine kinase inhibitor (TKI), was evaluated in patients with …

Osimertinib in Patients With Epidermal Growth Factor Receptor Mutation-Positive Non-Small-Cell Lung Cancer and Leptomeningeal Metastases: The BLOOM Study

JCH Yang, SW Kim, DW Kim, JS Lee… - Journal of clinical …, 2020 - pubmed.ncbi.nlm.nih.gov
Purpose In this phase I study (BLOOM), osimertinib, a third-generation epidermal growth
factor receptor (EGFR) tyrosine kinase inhibitor (TKI), was evaluated in patients with …

Osimertinib in Patients With Epidermal Growth Factor Receptor Mutation-Positive Non-Small-Cell Lung Cancer and Leptomeningeal Metastases: The BLOOM Study.

JCH Yang, SW Kim, DW Kim, JS Lee… - Journal of Clinical …, 2019 - europepmc.org
Purpose In this phase I study (BLOOM), osimertinib, a third-generation epidermal growth
factor receptor (EGFR) tyrosine kinase inhibitor (TKI), was evaluated in patients with …

Osimertinib in Patients With Epidermal Growth Factor Receptor Mutation–Positive Non–Small-Cell Lung Cancer and Leptomeningeal Metastases: The BLOOM Study

JCH Yang, SW Kim, DW Kim, JS Lee, BC Cho… - Journal of Clinical …, 2020 - cir.nii.ac.jp
抄録< jats: sec>< jats: title> PURPOSE</jats: title>< jats: p> In this phase I study (BLOOM),
osimertinib, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase …
[HTML] nih.gov

[HTML][HTML] Osimertinib in Patients With Epidermal Growth Factor Receptor Mutation–Positive Non–Small-Cell Lung Cancer and Leptomeningeal Metastases: The …

JCH Yang, SW Kim, DW Kim, JS Lee… - Journal of Clinical …, 2020 - ncbi.nlm.nih.gov
PURPOSE In this phase I study (BLOOM), osimertinib, a third-generation epidermal growth
factor receptor (EGFR) tyrosine kinase inhibitor (TKI), was evaluated in patients with …

Osimertinib in patients with epidermal growth factor receptor mutation-positive non-small-cell lung cancer and leptomeningeal metastases: The BLOOM study

JCH Yang, SW Kim, DW Kim, JS Lee… - Journal of Clinical …, 2020 - yonsei.elsevierpure.com
PURPOSE In this phase I study (BLOOM), osimertinib, a third-generation epidermal growth
factor receptor (EGFR) tyrosine kinase inhibitor (TKI), was evaluated in patients with …